logo
Lyft's Cash Flow Soars - But So Has the Stock - Is it Still a Buy?

Lyft's Cash Flow Soars - But So Has the Stock - Is it Still a Buy?

Globe and Mail13-05-2025

Lyft Inc. (LYFT) produced strong Q1 results with record trailing 12-month (TTM) free cash flow in an after-hours earnings release on May 8. Since then, LYFT stock has skyrocketed. It may have discounted the good news. But if LYFT keeps making high FCF margins, it could rise further.
LYFT closed at $17.21 on Monday, May 12, up from $12.58 on May 7 (+36.8%) before the earnings came out. It's now up to where it was before the sell-off in April, but still below its 6-month high of $18.59 on Nov. 11, 2024.
But does it still have more to go? Let's look at the results.
Strong Free Cash Flow Generation
Lyft reported that all its growth metrics were significantly higher than last year, and most were equal to or just slightly lower than last quarter. Its supplemental data deck shows these stats for gross bookings, quarterly rides, and riders.
For example, quarterly revenue at $1.45 billion was up +13.6% YoY, but down slightly from Q4 revenue of $1.55 billion (-6.45% QoQ).
Moreover, even though adjusted EBITDA (a measure of cash flow not including capex and working capital changes) was down slightly QoQ, its free cash flow (FCF), which includes these flows, was significantly higher. This can be seen in the table on page 16 of the deck:
It shows that in Q1 Lyft generated $240 million in FCF. That represents an amazing 19.4% of Lyft's Q1 revenue, vs. just 9.0% in Q4 and 9.96% in Q1 2024. In other words, its FCF has doubled, indicating the company has been squeezing more cash out of its operations. (In all fairness, the dip in Q4 FCF and FCF margins may have been an anomaly.)
In fact, over the trailing 12 months (TTM), LYFT has generated $920 million in FCF as seen on page 13 of its deck. This has been growing exponentially. It also represents 15.4% of almost $6 billion in TTM revenue.
As a result, if LYFT continues to generate between 15.4% and 19.4% FCF margins over the next year, we can expect that FCF will continue to soar. We can assume that it could come in at least 18% of the FCF of the estimated sales forecasts from analysts.
For example, Seeking Alpha shows that 40 analysts have an average revenue 2025 forecast of $6.48 billion. And for 2026, they forecast $7.20 billion in sales. As a result, FCF estimates are:
18% x $6.48 billion (2025 revenue est.) = $1.1664 billion FCF 2025
18% x $7.20 billion (2026 revenue est.) = $1.296 billion FCF 2026
This can help us set a price target, using an FCF yield metric.
LYFT Stock Price Targets
For example, LYFT now has a $7.234 billion market capitalization. That means that its TTM FCF of $920 million represents 12.7% of that market value (i.e., its FCF yield). That is the same as a multiple of 7.87x FCF (i.e., 1/0.127 = 7.874).
As a result, applying a 12.7% yield to the FCF forecasts results in a market cap forecast:
$1.1664 billion FCF (2025 est.) / 0.127 = $9.165 billion mkt cap
$1.296 billion FCF (2026 est.) / 0.127 = $10.204 billion mkt cap target
So, over the next 12 months (NTM), LYFT could be worth between $9.1 billion and $10.2 billion. That is between +26.7% and +41% higher than its present $7.2 billion mkt cap.
That implies its price target is still higher than today's price, i.e., between $21.81(i.e., 1.267 x $17.21) and$24.27 (1.41 x $17.21) per share, or $23.04 on average.
Just to be conservative, let's apply a higher FCF yield (i.e., a lower multiple). For example, using a 15% FCF yield (i.e., a 6.67x multiple):
$1.1664b x 6.667 = $7.78 billion market cap (2025 est), +7.5% over today
$1.296b x 6.667 = $8.64 billion mtk cap (2026 est.), + 19.4 % higher
The price target range for this more conservative forecast is $18.50 per share (+7.5%) to $20.55 (+19.4%), or $19.53 on average.
In other words, LYFT is worth somewhere between $19.53 and $23.04, depending on the FCF multiple used (i.e., 7.8x or 6.7x).
Analysts seem to agree. For example, 38 analysts surveyed by AnaChart.com now have an average price target of $22.00 per share.
The bottom line is that LYFT still has further to go on the upside, especially if its free cash flow and FCF margins remain strong over the next 12 months.
How to Play LYFT Stock
It's not uncommon for a stock that has risen so far so fast to take a beat. Normally, I would recommend shorting out-of-the-money (OTM) puts to set a lower buy-in target. But it may make sense to just watch things here.
For example, the June 13 expiration put option chain shows that the $16.00 strike price, 7% below Monday's closing price, has a midpoint premium of 46 cents. That represents a cash-secured short-put yield of 2.875% over the next month (i.e., $0.46 / $16.00 = 0.02875).
The problem is that Lyft stock could drop over the next month simply from profit-taking. This is even though it's worth more, as I have shown, and despite its low delta ratio of 27.5% and a $15.54 breakeven point (i.e., $16.00-$0.46). That is 9.7% below Monday's close of $17.21.
As a result, an investor might have a chance to make the same or better yield at a lower strike price. For example, if the $15.00 strike ends up with a 40 cents premium (up from 22 cents), the short-put yield is 2.667% and the breakeven point is $14.60 (i.e., -15% lower).
So, I recommend watching LYFT over the next 2 weeks and setting a buy-in target price. Over the next 12 months, there is a good likelihood of making a profit on LYFT at today's or a lower price.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?

Globe and Mail

time30 minutes ago

  • Globe and Mail

Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Disrupting the healthcare market Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk 's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Going abroad and personalization Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. HIMS Gross Profit Margin data by YCharts. Should you buy Hims & Hers stock? A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025

Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia
Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia

Globe and Mail

timean hour ago

  • Globe and Mail

Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia

There will prove to be many winners as artificial intelligence (AI) infrastructure continues to grow and AI end-uses expand. Nvidia (NASDAQ: NVDA) has been the Wall Street darling surrounding everything AI for the past two years. CoreWeave (NASDAQ: CRWV) has been getting the love most recently, though. Shares of the AI hyperscaler providing cloud services have soared about 185% in just the past month as of this writing. Nvidia stock has increased 24% in that time. CoreWeave just went public in late March, and the shares have jumped about 270% since that initial public offering (IPO). Investors may wonder if Nvidia's shine is fading, and it's time to buy CoreWeave instead. I'd argue that is flawed thinking, however. The growth isn't over for Nvidia Investors may be taking a breather after the early exponential gains in Nvidia stock. Growth in the business itself has also slowed, though that was inevitable. Sales of its advanced chips in the data center segment had been growing like a weed. Revenue in that segment has been increasing in each consecutive quarter for the last two years. In the most recent fiscal quarter, that growth rate slowed to 10%, though, as seen below. Despite that trend, it's clear AI demand hasn't yet peaked. Remember, these are still sequential quarterly increases in data center sales. For perspective, that fiscal first-quarter revenue was a 73% jump compared to the prior year period. Management also guided investors to expect further revenue growth in the current quarter. So, while an unsustainable growth rate slows, the company is still solidly in growth mode. Nvidia is more ubiquitous than you might think That's because it's not just Nvidia's advanced GPU and CPU chips driving sales and expanding AI infrastructure. Its AI ecosystem includes interconnect technologies, the CUDA (compute unified device architecture) software platform, and artificial intelligence processors that are part of many different types of architectures. CEO Jensen Huang recently touted Nintendo 's new Switch 2 gaming console, for example. The unit includes Nvidia's AI processors that Huang claims "sharpen, animate, and enhance gameplay in real time." Nvidia has a broad array of customers. As AI factories and data centers are built, it will continue to be a major supplier and one that investors should benefit from owning. Nvidia also invests in the AI sector. It makes sense to look at where the AI leader itself sees future gains. Nvidia thinks CoreWeave is a good investment One of the AI companies in which Nvidia holds a stake is CoreWeave. Nvidia should know CoreWeave well, too, as an important customer. CoreWeave leases data center space to companies needing the scalable, on-demand compute power it has control of from the 250,000 Nvidia chips it has purchased. It's a desirable option for enterprises that require significant computational power to process large amounts of data efficiently. There appears to be plenty of demand. But there is plenty of risk for investors, too. It just announced a new lease agreement to further increase capacity. Applied Digital, a builder and operator of purpose-built data centers, has agreed to deliver CoreWeave 250 megawatts (MW) of power load on a 15-year term lease at its recently built North Dakota data center campus. CoreWeave has the option to expand the load by an additional 150 MW in the future. Demand is quickly driving growth for CoreWeave. That's led investors to jump in and drive the stock higher in recent months. Valuation is just one major risk with CoreWeave. Customer concentration is another. Last year, Microsoft accounted for nearly two-thirds of revenue. CoreWeave also disclosed that 77% of 2024 revenue came from just its top two customers. CoreWeave is also spending massive amounts of capital to grow AI cloud capacity. It had about $5.4 billion of liquidity available as of March 31 and raised another $2 billion from a late May debt offering. That's approximately its level of capital expenditure in just the first quarter alone, though. CoreWeave has the risk, Nvidia has the profits That spending may pay off. But there are risks there as well. Customers could develop their own AI infrastructure or could redesign systems that don't require its services. CoreWeave stock also trades at a high valuation after the stock has soared. It recently had a price-to-sales (P/S) ratio of about 30. That could be cut in half this year with its strong sales growth, but it isn't earning any money yet. At the same time, Nvidia sports a price-to- earnings (P/E) ratio of about 30 based on this year's expected profits. Remember, too, that as CoreWeave grows, so do Nvidia's profits. Applied Digital CEO Wes Cummins said that its leased North Dakota data center campus will be full of Nvidia Blackwell class servers. I think the risk profile, financial picture, and massive potential for Nvidia make it the better AI stock to buy now. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store